These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10365744)

  • 1. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.
    Bril WS; MacLean PE; Kaijen PH; van den Brink EN; Lardy NM; Fijnvandraat K; Peters M; Voorberg J
    Haemophilia; 2004 Sep; 10(5):509-14. PubMed ID: 15357778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.
    Sawamoto Y; Prescott R; Zhong D; Saenko EL; Mauser-Bunschoten E; Peerlinck K; van den Berg M; Scandella D
    Thromb Haemost; 1998 Jan; 79(1):62-8. PubMed ID: 9459325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A.
    Fijnvandraat K; Turenhout EA; van den Brink EN; ten Cate JW; van Mourik JA; Peters M; Voorberg J
    Blood; 1997 Jun; 89(12):4371-7. PubMed ID: 9192760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.
    Boekhorst J; Verbruggen B; Lavergne JM; Costa JM; Schoormans SC; Brons PP; van Kraaij MG; Nováková IR; van Heerde WL
    Br J Haematol; 2005 Oct; 131(1):109-17. PubMed ID: 16173970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
    d'Oiron R; Pipe SW; Jacquemin M
    Haemophilia; 2008 Jul; 14 Suppl 3():138-46. PubMed ID: 18510534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.
    Thompson AR; Murphy ME; Liu M; Saenko EL; Healey JF; Lollar P; Scandella D
    Blood; 1997 Sep; 90(5):1902-10. PubMed ID: 9292523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.
    Laub R; Di Giambattista M; Fondu P; Brackmann HH; Lenk H; Saenko EL; Felch M; Scandella D
    Thromb Haemost; 1999 Jan; 81(1):39-44. PubMed ID: 9974372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia A patients with factor VIII inhibitor.
    Sugihara T; Takahashi I; Kojima T; Okamoto Y; Yamamoto K; Kamiya T; Matsushita T; Saito H
    Nagoya J Med Sci; 2000 May; 63(1-2):25-39. PubMed ID: 10911718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593-->Cys mutation using phage display.
    Bril WS; Turenhout EA; Kaijen PH; van den Brink EN; Koopman MM; Peters M; Voorberg J
    Br J Haematol; 2002 Nov; 119(2):393-6. PubMed ID: 12406075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients.
    Scandella DH
    Semin Thromb Hemost; 2000; 26(2):137-42. PubMed ID: 10919405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
    Goodeve AC; Williams I; Bray GL; Peake IR
    Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
    Boekhorst J; Lari GR; D'Oiron R; Costa JM; Nováková IR; Ala FA; Lavergne JM; VAN Heerde WL
    Haemophilia; 2008 Jul; 14(4):729-35. PubMed ID: 18503540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide.
    Vlot AJ; Wittebol S; Strengers PF; Turenhout EA; Voorberg J; van den Berg HM; Mauser-Bunschoten EP
    Br J Haematol; 2002 Apr; 117(1):136-40. PubMed ID: 11918545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.